COVID-19 vaccines using mRNA technology do not affect fertility outcomes during in-vitro fertilization (IVF), researchers found. Other new findings suggest the bacteria living in the small intestine may contribute to the risk for long COVID after infection with SARS-CoV-2.

Swiss-listed drugmaker ObsEva is abandoning the current program for the company’s drug prospect nolasiban after the agent aimed at boosting pregnancy following in-vitro fertilization (IVF) failed a late-stage study in Europe.